Mohit Agarwal
Nephrology · Phoenix, AZNPI 1407061781
Payments from drug & device makers
Across 248 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$593
- Otsuka America Pharmaceutical, Inc.$579
- AstraZeneca$542
- OPKO Pharmaceuticals, LLC$385
- Travere Therapeutics, Inc.$324
- Vifor Pharma, Inc.$291
- plus $3K from 24 others
What the payments were for
- Food & beverage$5,05396%
- Education$2374%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 32 | $593 |
| Otsuka America Pharmaceutical, Inc. | 26 | $579 |
| AstraZeneca(2 entities) | 30 | $542 |
| OPKO Pharmaceuticals, LLC | 20 | $385 |
| Travere Therapeutics, Inc. | 15 | $324 |
| Vifor Pharma, Inc. | 14 | $291 |
| Bayer | 16 | $268 |
| GSK | 14 | $238 |
| Daiichi Sankyo Inc. | 10 | $237 |
| Akebia Therapeutics Inc | 10 | $225 |
| Mallinckrodt Hospital Products Inc. | 7 | $192 |
| Novo Nordisk | 4 | $168 |
| Novartis | 7 | $161 |
| Ardelyx, Inc. | 7 | $140 |
| Boehringer Ingelheim | 5 | $136 |
| Baxter Healthcare | 1 | $124 |
| Vantive US Healthcare LLC | 1 | $105 |
| Calliditas Therapeutics US Inc. | 5 | $102 |
| Aurinia Pharma U.S., Inc. | 5 | $102 |
| ANI Pharmaceuticals, Inc. | 4 | $93 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $61 |
| Sanofi | 3 | $45 |
| Pfizer | 2 | $37 |
| Merck | 1 | $30 |
| Cormedix Inc. | 1 | $26 |
| Veloxis Pharmaceuticals, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Fresenius USA Marketing, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Gilead | 1 | $13 |
How this compares
$5,290 in reported general payments places this provider in the 70th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 129 | $103,965 |
| OzempicSemaglutide | 65 | $72,413 |
| KerendiaFinerenone | 61 | $68,683 |
| LokelmaSodium Zirconium Cyclosilicate | 93 | $56,305 |
| MounjaroTirzepatide | 25 | $32,414 |
| JardianceEmpagliflozin | 18 | $19,097 |
| Cinacalcet Hcl | 21 | $12,548 |
| ProsolParenteral Amino Acid 20% No.1 | 56 | $7,660 |
| Sevelamer Carbonate | 13 | $5,630 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $5,009 |
| Calcitriol | 230 | $4,496 |
| Midodrine Hcl | 26 | $2,419 |
| Nifedipine ErNifedipine | 88 | $2,269 |
| Potassium Citrate ErPotassium Citrate | 15 | $2,087 |
| Hydralazine Hcl | 124 | $2,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $542 | $160,270222 claims |
| Novo NordiskOzempic | $168 | $72,41365 claims |
| BayerKerendia | $268 | $68,68361 claims |
| Boehringer IngelheimJardiance | $136 | $19,09718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 259 nephrology providers in Arizona.
Other nephrology in Phoenix
- Leslie ThomasPhoenix$3.1M
- Hasan KhamashPhoenix$1.3M
- Roxana NeyraPhoenix$1M
- Hassan HachemPhoenix$372K
- Sungchun LeePhoenix$341K
- Shouwen WangPhoenix$195K
- Nina PatelPhoenix$174K
- Yuzana ZawPhoenix$159K
- Alexander NimriPhoenix$133K
- Samer Bani HaniPhoenix$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.